Copyright
©The Author(s) 2021.
World J Gastroenterol. Apr 7, 2021; 27(13): 1330-1340
Published online Apr 7, 2021. doi: 10.3748/wjg.v27.i13.1330
Published online Apr 7, 2021. doi: 10.3748/wjg.v27.i13.1330
Table 1 Characteristic of the 181 patients
Parameters | Patients, n = 181 |
Age in yr | 52.16 ± 9.73 |
Sex, men/women | 159/22 |
Cause of liver disease, hepatitis B/C/B and C/others | 163/3/1/14 |
Tumor size, < 5 cm/≥ 5 cm, < 10 cm/≥ 10 cm | 39/86/56 |
Number of tumors, 1/2/≥ 3 | 82/12/87 |
Liver cirrhosis, no/yes | 48/133 |
Ascites, no/small/moderate-massive | 91/70/20 |
CTPV, no/yes | 158/23 |
Invade left and right liver lobes, no/yes | 119/62 |
Type of gross pathology, massive/nodular/diffuse | 112/59/10 |
PVTT type, I/II/III/IV | 29/77/68/7 |
Inferior vena cava tumor thrombus, no/yes | 171/10 |
Arteriovenous fistula, no/yes | 125/56 |
Total bilirubin, µmol/L | 17.1 (12.3-24.7) |
Prealbumin, mg/L | 110 (79-147) |
Albumin, g/L | 37 ± 4.8 |
Hemoglobin, g/L | 127 (115-142) |
WBC, 109/L | 5.1 (3.925-6.505) |
PLT, 109/L | 116 (81- 179.5) |
INR | 1.12 (1.055-1.205) |
PT, S | 14.3 (13.7-15.25) |
APTT, S | 39.5 (37-42.8) |
ALT, U/L | 46 (31-71.5) |
AST, U/L | 65 (46-109.5) |
GGT, U/L | 211 (124.5-352.5) |
Cholinesterase, kU/L | 4.5 (3.065-5.78) |
Creatinine, µmol/L | 68 (57.7-78.1) |
AFP, µg/L | 1210 (82.905-1210) |
Child-Pugh grade, A/B/C | 123/55/3 |
ECOG score, 0/1/2/3 | 8/142/29/2 |
ALBI grade, 1/2/3 | 56/120/5 |
MELD score | 7.67 (6.08-9.54) |
Overall survival time, mo | 4.8 (2.5-8.85) |
Table 2 Univariate analysis of survivors vs non-survivors at 3 mo after transarterial chemoembolization
Parameters | Survivors, n = 125 | Non-survivors, n = 56 | P value |
Age in yr | 52.56 ± 9.966 | 51.27 ± 9.212 | 0.18 |
Sex, men/women | 114/11 | 45/11 | 0.04 |
Cause of liver disease, hepatitis B/C/B and C/others | 113/1/0/11 | 50/2/1/3 | 0.157 |
Tumor size, < 5 cm/≥ 5 cm, < 10 cm/≥ 10 cm | 29/57/39 | 10/29/17 | 0.659 |
Number of tumors, 1/2/≥ 3 | 62/10/53 | 20/2/34 | 0.06 |
Liver cirrhosis, no/yes | 36/89 | 12/44 | 0.299 |
Ascites, no/small/moderate-massive | 68/47/10 | 23/23/10 | 0.087 |
CTPV, no/yes | 110/15 | 48/8 | 0.67 |
Invade left and right liver lobes, no/yes | 85/40 | 34/22 | 0.34 |
Type of gross pathology, massive / nodular and diffuse | 78/47 | 34/22 | 0.829 |
PVTT type, I/II/III/IV | 24/52/44/5 | 5/25/24/2 | 0.354 |
Inferior vena cava tumor thrombus, no/yes | 119/6 | 52/4 | 0.775 |
Arteriovenous fistula, no/yes | 89/36 | 36/20 | 0.352 |
Total bilirubin, µmol/L | 15 (11.15-21.75) | 22.25 (17.175-32) | < 0.01 |
Prealbumin, mg/L | 119 (87-159.5) | 91.5 (67.25-120.5) | < 0.01 |
Albumin, g/L | 36.407 ± 4.749 | 37.205 ± 4.853 | 0.758 |
Hemoglobin, g/L | 127 (115-142) | 127 (113.25-143) | 0.89 |
WBC, 109/L | 5.06 (4.06-6.27) | 5.09 (3.61-6.72) | 0.87 |
PLT, 109/L | 119.00 (86.00-180.50) | 111.00 (69.25-178.25) | 0.15 |
INR | 1.11 (1.06-1.19) | 1.12 (1.05-1.26) | 0.33 |
PT, S | 14.20 (13.70-15.20) | 14.35 (13.70-15.78) | 0.38 |
APTT, S | 39.60 (37.25-42.80) | 39.35 (36.32-42.85) | 0.47 |
ALT, U/L | 41.00 (29.50-62.00) | 58.00 (41.25-85.75) | < 0.01 |
AST, U/L | 56.00 (41.00-81.00) | 109.00 (72.00-161.75) | < 0.01 |
GGT, U/L | 188.00 (109.00-300.50) | 256.00 (186.00-415.25) | < 0.01 |
Cholinesterase, kU/L | 4.88 (3.44-5.84) | 3.89 (2.69-5.4675) | 0.02 |
Creatinine, µmol/L | 68.60 (58.20-77.25) | 66.95 (54.98-79.60) | 0.63 |
AFP, µg/L | 1210 (47.86-1210) | 1210 (270-1210) | 0.34 |
Child-Pugh grade, A/B/C | 94/30/1 | 29/25/2 | < 0.01 |
ECOG score, 0/1/2/3 | 8/102/14/1 | 0/40/15/1 | 0.016 |
ALBI grade, 1/2/3 | 43/79/9 | 13/41/2 | 0.31 |
MELD score | 7.53 (5.88-9.02) | 9.10 (7.08-11.19) | < 0.01 |
Table 3 Multivariate analysis of short-term and long-term survival
Variables | Short-term survival | Long-term survival | ||
OR (95%CI) | P value | OR (95%CI) | P value | |
Total bilirubin, µmol/L | 1.027 (1-1.054) | 0.046 | ||
AST, U/L | 1.014 (1.006-1.021) | P < 0.01 | ||
Sex | ||||
Men | 1 | |||
Women | 2.832 (1.025-7.828) | 0.045 | ||
Type of gross pathology | ||||
Massive | 1 | |||
Nodular and diffuse | 0.197 (0.075-0.521) | 0.001 | ||
Number of tumors | ||||
1 | 1 | |||
2 | 1.365 (0.283-6.581) | 0.698 | ||
3 | 5.809 (1.563-21.594) | 0.009 |
Table 4 Univariate analysis of survivors vs non-survivors at 12 mo after transarterial chemoembolization
Parameters | Survivors, n = 31 | Non-survivors, n = 150 | P value |
Age in yr | 54.770 ± 10.724 | 51.800 ± 9.400 | 0.225 |
Sex, men/women | 28/3 | 131/19 | 0.871 |
Cause of liver disease, hepatitis B/C/B and C/others | 30/0/0/1 | 133/3/1/13 | 0.751 |
Tumor size, < 5 cm/≥ 5 cm, < 10 cm/≥ 10 cm | 11/14/6 | 28/72/50 | 0.081 |
Number of tumors, 1/2/≥ 3 | 21/4/6 | 61/8/81 | 0.002 |
Liver cirrhosis, no/yes | 4/27 | 44/106 | 0.059 |
Ascites, no/small/moderate-massive | 16/11/4 | 75/59/16 | 0.892 |
CTPV, no/yes | 26/5 | 132/18 | 0.74 |
Invade left and right liver lobes, no/yes | 26/5 | 93/57 | 0.019 |
Type of gross pathology, massive/nodular and diffuse | 13/18 | 99/51 | 0.012 |
PVTT type, I/II, III/IV | 7/10/11/3 | 22/67/57/4 | 0.155 |
Inferior vena cava tumor thrombus, no/yes | 30/1 | 141/9 | 0.854 |
Arteriovenous fistula, no/yes | 21/10 | 104/46 | 0.861 |
Total bilirubin, µmol/L | 19.550 (11.200-33.400) | 16.600 (12.900-24.000) | 0.436 |
Prealbumin, mg/L | 124.500 (86.750-160.500) | 105.000 (78.000-142.000) | 0.163 |
Albumin, g/L | 37.047 ± 5.635 | 36.813 ± 4.622 | 0.669 |
Hemoglobin, g/L | 132.500 (117.500-146.500) | 125.000 (115.000-142.000) | 0.316 |
WBC, 109/L | 4.565 (3.398-5.850) | 5.100 (4.050-6.610) | 0.284 |
PLT, 109/L | 89.000 (63.250-126.000) | 119.000 (87.000-182.000) | 0.046 |
INR | 1.120 (1.070-1.253) | 1.110 (1.050-1.200) | 0.281 |
PT, S | 14.400 (13.850-15.875) | 14.300 (13.700-15.200) | 0.266 |
APTT, S | 39.200 (36.450-42.075) | 39.700 (37.100-42.900) | 0.541 |
ALT, U/L | 46.500 (38.500-72.000) | 45.000 (30.000-72.000) | 0.770 |
AST, U/L | 56.500 (41.750-83.750) | 71.000 (46.000-115.000) | 0.108 |
GGT, U/L | 177.500 (72.250-265.250) | 216.000 (132.000-356.000) | 0.036 |
Cholinesterase, kU/L | 4.25 (2.775-5.905) | 4.51 (3.08-5.79) | 0.945 |
Creatinine, µmol/L | 71.300 (61.475-79.500) | 67.600 (57.400-78.100) | 0.220 |
AFP, µg/L | 568 (15.13~1210) | 1210 (97.335-1210) | 0.188 |
Child-Pugh grade, A/B/C | 19/11/1 | 104/44/2 | 0.373 |
ECOG score, 0/1/2/3 | 4/24/3/0 | 4/118/26/2 | 0.086 |
ALBI grade, 1/2/3 | 13/16/2 | 43/104/3 | 0.09 |
MELD score | 7.130 (5.548-9.315) | 7.860 (6.070-9.790) | 0.348 |
- Citation: Chen KL, Gao J. Factors influencing the short-term and long-term survival of hepatocellular carcinoma patients with portal vein tumor thrombosis who underwent chemoembolization. World J Gastroenterol 2021; 27(13): 1330-1340
- URL: https://www.wjgnet.com/1007-9327/full/v27/i13/1330.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i13.1330